For a patient receiving chemotherapy, is famotidine (H2‑blocker) preferred over omeprazole (proton‑pump inhibitor) for gastric protection, and what are the recommended dosing and safety considerations?

Famotidine vs Omeprazole During Chemotherapy

For patients receiving chemotherapy, omeprazole (or other PPIs) is preferred over famotidine for gastric protection, based on superior efficacy in preventing chemotherapy-induced gastroduodenal injury. However, critical drug-drug interactions with certain chemotherapy agents must be considered before prescribing either agent.

Key Drug Interactions: Critical Consideration

Chemotherapy Agents with pH-Dependent Absorption

For patients on dasatinib, nilotinib, or glecaprevir/pibrentasvir, neither PPIs nor H2-blockers should be used routinely 1, 2:

• Dasatinib: Both H2-blockers and PPIs reduce dasatinib exposure due to pH-dependent solubility. Antacids (given ≥2 hours before or after dasatinib) should be used instead 1
• Glecaprevir/pibrentasvir: Omeprazole 40 mg decreases glecaprevir Cmax by 64%. While no dose adjustment is recommended per labeling, doses >40 mg omeprazole equivalent should be avoided 2
• Ledipasvir/sofosbuvir: H2-antagonists can be given simultaneously or 12 hours apart (≤famotidine 40 mg equivalent); PPIs allowed simultaneously (≤omeprazole 20 mg equivalent) 3

Efficacy for Gastric Protection

Evidence Supporting PPI Superiority

Omeprazole 20 mg once daily is significantly more effective than famotidine or misoprostol in preventing chemotherapy-induced gastroduodenal injury 4:

• In a randomized trial of 182 cancer patients receiving CMF or 5-FU chemotherapy, omeprazole prevented endoscopic worsening while placebo and misoprostol groups showed significant increases in mucosal injury
• Gastric and duodenal ulcers were significantly less frequent with omeprazole vs placebo after both CMF and 5-FU (P<0.05)
• Epigastric pain/heartburn were significantly reduced with omeprazole vs placebo (P<0.01) or misoprostol (P<0.001)

A 2025 randomized crossover trial demonstrated that pantoprazole 40 mg daily significantly reduced delayed chemotherapy-induced nausea and vomiting 5:

• Complete absence of delayed CINV: 51.4% with pantoprazole vs 39.3% with placebo (OR 2.2,95% CI 1.18-4.12, P=0.01)
• Nausea scores significantly lower with pantoprazole (P=0.006)
• 50.4% of patients preferred pantoprazole vs 25.2% preferring placebo

H2-Blocker Efficacy

Standard-dose H2-blockers provide inadequate gastric protection during chemotherapy 6, 7:

• Standard-dose H2-antagonists reduce duodenal but not gastric ulcers in NSAID users 7
• Double-dose H2-antagonists show variable efficacy, with benefit primarily in H. pylori-positive patients 7
• PPIs provide superior acid suppression (up to 36 hours) compared to H2-blockers (37-68% suppression over 24 hours) 8

Recommended Dosing

For Chemotherapy-Induced Gastric Protection

Omeprazole 20 mg once daily (or equivalent PPI) is the evidence-based dose 4:

• Lansoprazole 30 mg once daily
• Esomeprazole 20 mg once daily
• Pantoprazole 40 mg once daily
• Rabeprazole 20 mg once daily 2

If H2-blocker must be used (e.g., due to drug interactions):

• Famotidine 20 mg twice daily 2
• Ranitidine 150 mg twice daily (if available)
• Note: Standard once-daily dosing is insufficient 7

Timing Considerations

• PPIs: Take 30 minutes before breakfast for optimal effect 9
• Famotidine: Can be taken without regard to meals; peak levels occur in 1-3 hours 9
• Duration: Continue throughout chemotherapy cycles and for 5 days after each cycle 5

Safety Considerations

PPI Safety Profile

Long-term PPI use carries known risks 10:

• Osteoporosis and fracture risk
• Gastrointestinal infections (C. difficile)
• Pneumonia
• Potential drug-drug interactions via CYP2C19 and CYP3A4

Famotidine Safety Profile

Famotidine has fewer long-term safety concerns 9:

• Minimal first-pass metabolism
• 65-70% renal elimination (requires dose adjustment in renal impairment)
• Elimination half-life: 2.5-3.5 hours
• 15-20% protein bound

Dose adjustment in renal impairment 9:

• CrCl <30 mL/min: Reduce dose by 50% or increase dosing interval to every 36-48 hours
• Hemodialysis: Give dose after dialysis

Common Pitfalls

1. Assuming H2-blockers are equivalent to PPIs: They are not—PPIs provide superior gastric protection during chemotherapy 4

2. Using standard-dose H2-blockers: If H2-blockers must be used, double-dose (famotidine 20 mg BID) is required 7

3. Ignoring pH-dependent drug interactions: Always check if the chemotherapy regimen includes dasatinib, nilotinib, or other pH-sensitive agents before prescribing acid suppressants 1, 2

4. Forgetting renal dose adjustment: Famotidine requires dose reduction in renal impairment; omeprazole does not 9

5. Discontinuing prophylaxis too early: Continue acid suppression for 5 days after each chemotherapy cycle 5

Clinical Algorithm

Step 1: Identify chemotherapy regimen

• If dasatinib/nilotinib → Use antacids only (±2 hours from chemotherapy) 1
• If glecaprevir/pibrentasvir → Limit omeprazole to ≤40 mg or use famotidine 2
• All other regimens → Proceed to Step 2

Step 2: Assess renal function

• CrCl ≥30 mL/min → Omeprazole 20 mg daily preferred 4
• CrCl <30 mL/min → Consider famotidine 20 mg daily (reduced dose) or omeprazole 20 mg daily 9

Step 3: Monitor and adjust

• If breakthrough symptoms on omeprazole → Consider pantoprazole 40 mg daily 5
• If PPI contraindicated → Famotidine 20 mg BID (not once daily) 2, 7